Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Aroa Biosurgery Ltd (ARX) Share Price & Analysis

ARX Stock Chart & Stats

A$0.49-A$0.07(-11.82%)
At close: 4:10 PM GMT+11
AU$0.5AU$0.55AU$0.63 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
AUD 0.52 - AUD 0.55
52-Week Range
AUD 0.48 - AUD 0.80
Previous Close
AUD 0.54
Volume
N/A
Average Volume (3M)
257.85K
Market Cap
AUD 190.25M
Enterprise Value
AUD 196.49M
Total Cash (Recent Filing)
AUD 22.60M
Total Debt (Recent Filing)
AUD 5.31M
Price to Earnings (P/E)
45.8
Beta
0.64
Next Earnings
Nov 26, 2026 (Est.)
EPS Estimate
0
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Revenue growth of this magnitude indicates expanding adoption of Aroa’s ECM-based products across surgical and wound-care applications. Continued top-line momentum can improve operating leverage, support broader commercialization, and strengthen the company’s ability to fund product and market expansion.

High Gross Margins

Consistently high gross margins provide an attractive economic base for a medical-device business, leaving more revenue available to cover selling, research, and administrative costs. This supports future profitability if sales continue scaling and indicates the products retain meaningful economic value.

Conservative Balance Sheet

Low leverage and substantial equity provide financial resilience as Aroa develops its commercial platform and expands product adoption. A conservative balance sheet reduces interest and refinancing pressure, preserves strategic flexibility, and gives the company greater capacity to absorb execution variability.

Bears Say

Profitability Only Recently Positive

The move into profitability is encouraging, but it has occurred only in the latest annual period after several years of losses. This limited track record means the durability of earnings remains unproven, particularly if growth slows or commercialization costs remain elevated.

Volatile Cash Generation

Positive operating and free cash flow in 2026 improves financial quality, but the preceding multi-year deficits show that cash conversion has been inconsistent. Sustained positive cash generation is still needed to demonstrate that reported earnings can reliably fund operations and growth without additional financing.

Modest Net Margin

The gap between very strong gross margins and a modest net margin indicates that operating and other expenses still absorb much of the company’s product economics. Limited bottom-line conversion leaves less protection against execution challenges and makes sustained scale benefits important.

Aroa Biosurgery Ltd News

ARX FAQ

What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.48 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$190.25M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
Aroa Biosurgery Ltd’s next earnings report is estimated for Nov 26, 2026 (not yet confirmed), which is in 24 days.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Aroa Biosurgery Ltd released its earnings results on May 25, 2026. The company reported AU$0.016 earnings per share for the quarter, beating the consensus estimate of AU$0.004 by AU$0.012.
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate is 0.00.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,902,650 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Aroa Biosurgery Ltd reported an EPS of AU$0.016 in its last earnings report, beating expectations of AU$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology